Indatuximab Biosimilar Antibody-Drug Conjugate (CD138) for Research

Cat No.: GMP-Bios-ab-271

Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-ab-271-1mg 1mg
GMP-Bios-ab-271-10mg 10mg
GMP-Bios-ab-271-100mg 100mg
GMP-Bios-ab-271-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody
INN Name Indatuximab
TargetSDC1
FormatWhole mAb ADC
Derivation
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2011
Year Recommended2012
CompaniesBiotest AG
Conditions Approvedna
Conditions Activena
Conditions Discontinuedna
Development Techna



About target - SDC1

1. Protein Syndecan-1

2. Gene SDC1

3. Organism Homo sapiens (Human)

Function
Cell surface proteoglycan that bears both heparan sulfate and chondroitin sulfate and that links the cytoskeleton to the interstitial matrix. Regulates exosome biogenesis in concert with SDCBP and PDCD6IP (PubMed:22660413).